Abstract
In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).
MeSH terms
-
Adamantane / analogs & derivatives
-
Adamantane / therapeutic use
-
Alanine / analogs & derivatives
-
Alanine / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Benzhydryl Compounds / therapeutic use
-
Benzylamines / therapeutic use
-
Dipeptides / therapeutic use
-
Drug Approval*
-
Drug Combinations
-
Glucosides / therapeutic use
-
Humans
-
Oxymetazoline / therapeutic use
-
Primary Health Care
-
United States
-
United States Food and Drug Administration*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Benzhydryl Compounds
-
Benzylamines
-
Dipeptides
-
Drug Combinations
-
Glucosides
-
dapagliflozin
-
dupilumab
-
brodalumab
-
Oxymetazoline
-
safinamide
-
saxagliptin
-
sarilumab
-
Alanine
-
Adamantane